INTRODUCTION
In 1949, Haldane [1] suggested that b-thalassemia trait may protect red cells from Plasmodium infection, and thus humans from clinical malaria. This general hypothesis -that red cell variants modulate susceptibility to malaria -has since been investigated for hemoglobin (Hb) mutants, enzymopathies, ABO blood groups, and acquired iron deficiency. Specifically, studies have confirmed that protection from severe falciparum malaria is conferred in African children by heterozygosity for HbA and HbS (HbAS or 'sickle-cell trait'), heterozygosity and homozygosity for HbC (HbAC and HbCC; reviewed in [2] ), hemizygosity for glucose-6-phosphate dehydrogenase (G6PD) deficiency [3] , and lack of blood group antigens A and B (i.e., type O) [4] (Table 1 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] ). HbAS and HbCC seem to provide substantial protection from severe disease (91 and 73%, respectively) [2] , but little or no protection from parasitemia, suggesting that these traits interfere specifically with the pathogenic mechanisms governing transitions from parasitization to severe and fatal infections. From a biological point-ofview, these insights highlight the coevolution of host and parasite and serve as a model of balancing selection. From a clinical perspective, these PLASMODIUM SPECIES Plasmodium spp. parasites are vector-borne pathogens that infect the red cells of reptiles, birds, and primates. Five species of Plasmodium (Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi) cause malaria in humans. P. falciparum and P. vivax cause most episodes of malaria, and are therefore the focus of this review. P. falciparum is endemic in tropical areas worldwide but is transmitted most intensely in sub-Saharan Africa, where it kills more than 500 000 children each year [19] . P. vivax is endemic in South and Southeast Asia, South America, and the Western Pacific, and is a major cause of morbidity in these regions.
All five Plasmodium species are transmitted by female Anopheles spp. mosquitoes during a blood meal on humans. After injection into the skin, sporozoites migrate to the liver, develop within hepatocytes for 7-10 days, and emerge as a large population of merozoites capable of invading red cells. This new blood stage of asexual parasite development produces the clinical syndrome of malaria, and is marked by repeated cycles of merozoite invasion of red cells, parasite maturation and multiplication within red cells, and merozoite egress from red cells. During this process, a small fraction of parasites differentiates into sexual gametocytes, which are ingested by another female anopheline mosquito. In this vector, gametocytes undergo sexual recombination and eventually develop into sporozoites, which migrate to the mosquito's salivary glands and await inoculation into the next human host.
IMPACT OF RED CELL VARIANTS ON MALARIA
Malaria is the clinical syndrome that results from infection with Plasmodium spp. parasites. The symptoms of malaria are notoriously nonspecific, but fever is a cardinal finding in nearly all clinically significant infections. Additionally, the clinical outcomes of blood-stage infections vary widely in severity from mild, uncomplicated malaria to severe, life-threatening malaria, which encompasses the often nonoverlapping syndromes of cerebral malaria, severe anemia, and respiratory distress. An estimated 451 million clinical cases of falciparum malaria occurred in 2007, largely in subSaharan Africa, and nearly 3 billion people are at annual risk of infection with P. vivax, largely in Central Asia [20, 21] . As noted earlier, the interactions between red cell variants and P. falciparum parasites have generated longstanding interest, and recent studies have begun to define the mechanisms of these relationships. Even today, there exist few data on the impact of red cell variants upon other Plasmodium species and the malaria syndromes they cause.
Plasmodium falciparum malaria
Recent studies of P. falciparum in West Africa have underscored the influence of red cell variants on human malaria cases. In extending an earlier study of the influence of known Hb mutants on severe falciparum malaria [5] , Timmann et al. [22 & ] performed a genome-wide association study (GWAS) of severe malaria in Ghanaian children to identify novel polymorphisms that modulate susceptibility to this disease. In this study, four loci achieved genome-wide significance: known variants at the b-globin and ABO blood group loci, a locus near the MARVELD3 gene, which encodes an endothelial tight-junction protein, and a locus in the ATP2B4 gene, which encodes a Ca 2þ pump. Although this
KEY POINTS
SAO and the 'Mahidol' and 'Mediterranean' variants of G6PD deficiency protect against vivax malaria, reduce P. vivax parasite density, or both.
b-Globin variants HbS and HbC confer substantial protection from severe falciparum malaria but enhance the passage of P. falciparum to mosquitoes, which may contribute to onward transmission in human populations.
Aberrant host miRNA profiles in HbS-containing red cells may impair P. falciparum development by forming chimeric fusion mRNA with parasite transcripts and adversely affecting protein translation.
HbS and HbC interfere with parasite-dependent remodeling of red cell cytoskeletal actin and transit of parasite proteins to the red cell surface.
The chronic release of heme from HbS red cells activates heme oxygenase-1, which mediates protection from cerebral malaria in a murine model, suggesting a role for the innate immune system in the malaria protective effects of sickle-cell trait in humans.
Ca 2þ pump is expressed in numerous tissues, it serves as the principal pump in red cells, in which P. falciparum growth may conceivably be disrupted by alterations in Ca 2þ homeostasis. This finding was replicated by the authors in a separate GWAS study in Gambian children, and awaits functional exploration as a component of yet another mechanism by which red cell variants may attenuate the virulence of P. falciparum.
A study of P. falciparum transmission in Burkina Faso elegantly demonstrated that human b-globin mutations influence the transmissibility of P. falciparum parasites. Gouagna et al.
[23] employed several study designs to test whether HbC and HbS children infected with P. falciparum transmit parasites more efficiently to anopheline mosquitoes. In cross-sectional surveys, they noted a higher prevalence and greater density of gametocytes in HbC children, and using in-vivo and ex-vivo blood feeding experiments they reported that HbC or HbS [compared with homozygous HbA (HbAA)] red cells were associated with two-fold to four-fold higher transmission of parasites to mosquitoes. Therefore, these prevalent b-globin mutations seem to protect individual carriers from life-threatening disease states while at the same time promoting transmission of parasites through mosquito vectors and into human populations. These data highlight how malaria parasites and humans have coevolved: while P. falciparum parasites drive the continued inheritance of HbS and HbC in human generations, these mutations enhance the continued transmission of these parasites into successive mosquito populations.
In Uganda, Gong et al.
[24 & ] conducted a longitudinal study of HbAA and HbAS children to better characterize the natural history of P. falciparum infections and the patterns of protection from asymptomatic parasitemia and symptomatic malaria. In a mesoendemic setting, 601 children aged 1-10 years were followed frequently over 18 months for parasite genotypes, patent parasitemia, and malaria episodes. As compared with HbAA children, HbAS children had a lower 'molecular force of infection' (i.e., the number of new parasite strains in a person per year), suggesting that In a longitudinal study of Tanzanian children with frequent, active follow-up visits, iron deficiency at routine, well child visits reduced the risk of subsequent parasitemia, severe malaria, and malaria-attributable mortality. Because diagnosing iron deficiency in such settings is challenging, the authors employed multiple definitions of iron deficiency using various cut-off values for serum levels of ferritin, C-reactive protein, and transferrin receptor -all of which were associated with similar risk reductions. These data suggest that iron deficiency protects children from severe and fatal falciparum malaria, although it remains unclear if the mechanisms of this effect occur principally in the red cells or sera of these children.
Plasmodium vivax malaria
Southeast Asian ovalocytosis (SAO; conferred by the band 3 deletion SLC4AD27) is lethal in the homozygous state but achieves high prevalence in the heterozygous state in Papua New Guinea (PNG), suggesting balancing selection conferred by some survival advantage in this geographic area. SAO has previously been associated with reduced risk of cerebral P. falciparum malaria in PNG [18] , and Rosanas-Urgell et al. [26 && ] hypothesized that it may also confer protection from P. vivax malaria. In three complementary clinical studies in PNG, SAO was associated with a 43% reduced incidence of vivax malaria in a prospective cohort of children, and possibly with reduced risk of severe vivax malaria as well. SAO was not associated with other protective red cell phenotypes, such as low expression of the Duffy antigen receptor for chemokines (an invasion receptor for P. vivax), or the presence of a-thalassemia. Additional field-based and laboratory-based studies are needed to confirm and elucidate the mechanism of this newly discovered protection.
Two recent studies have explored the influence of G6PD deficiency on P. vivax infection. Louicharoen et al. [27] investigated the G6PD-Mahidol variant, which reduces enzyme function by 5-32%, and is prevalent in several ethnic groups in malaria endemic areas of Southeast Asia. Population genetics analyses indicated significant, recent positive selection of G6PD-Mahidol in human populations, suggesting it confers a clinical benefit to carriers. In partial support of this possibility, clinical studies found an allele-dependent reduction in P. vivax density in both men and women; however, this variant was not associated with the frequency of malaria episodes or the prevalence of P. falciparum parasitemia.
In complementary work, Leslie et al. [28] conducted a case-control study of P. vivax malaria and its relationship with G6PD deficiency on the Afghanistan-Pakistan border. Phenotypic G6PD deficiency was significantly reduced among the cases of vivax malaria, and genotypic deficiency (G6PD-Mediterranean) was reduced in both men and women, providing further evidence that this class II-III variant protects carriers from vivax malaria. Taken together, these studies establish an evidence base for exploring the impact of red cell variants upon vivax malaria, and suggest that this disease has historically been severe enough to impair fitness and to naturally select red cell variants that are potentially deleterious.
MECHANISMS OF PROTECTION AGAINST MALARIA
The mechanisms by which red cell variants confer protection from malaria have not been definitively elucidated (Fig. 1) [29] and [34] ). Although recent studies have elucidated remarkable cellular, molecular, and immunological impacts of HbS upon red cell parasitization and malaria risk, further efforts are required to more finely characterize these phenomena and exploit them in the development of clinical interventions.
Effects on parasite pathogenicity
Two studies have highlighted the dialogue between red cells and P. falciparum and explored how these interactions are impacted by b-globin mutations. HbCC and HbAS red cells reduce the expression and impair the function of P. falciparum erythrocyte membrane protein 1 (PfEMP1) variants [35, 36] , which principally mediate the binding of infected red cells to extracellular host receptors. Using electron tomography of infected HbAA, HbCC, and compound heterozygous HbS and HbC (HbSC) red cells, Cyrklaff et al. [30 && ] investigated the intraerythrocytic machinery that P. falciparum establishes de novo and utilizes to traffic its PfEMP1 proteins to the red cell surface. In HbAA red cells, parasites mined their host cell actin and used it to construct (c) Activation of the innate immune system by infected red cells, parasite DNA, and free heme can alter the balance of proinflammatory and antiinflammatory cytokines to influence pathogenesis, as described by Ferreira et al. [33] . These investigators propose that the chronic release of free heme from HbScontaining red cells activates heme oxygenase-1, which then mediates tolerance of Plasmodium parasites in a murine model of cerebral malaria. (d) Plasmodium spp. parasites may be cleared more efficiently by the adaptive immune system when infecting red cell variants, although Tan et al. [32 & ] report that children with b-globin variants did not acquire antibodies to P. falciparum proteins more rapidly or efficiently than children with normal b-globins. Originally published in Taylor SM, Cerami C, Fairhurst RM. Hemoglobinopathies: Slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis. PLoS Pathogens 2013; 9:e1003327 [29] . Made available under the Creative Commons Attribution CCBY license [29] .
an intracellular network for transporting parasite proteins -including PfEMP1 -to the red cell surface. In HbCC and HbSC red cells, parasites developed normally, but the cytoskeletal network was aberrant in appearance, and the transport of parasite-derived proteins to the red cell surface was impaired. Because these parasite-derived surface proteins mediate the pathogenicity and immunogenicity of infected red cells, these findings suggest new avenues by which their expression may be modified for clinical benefit.
In another study, LaMonte et al.
[31 && ] explored the interactions of human red cell microRNAs (miRNAs) upon P. falciparum development, and how this relationship may be modified by HbS. The premises of their experiments were that P. falciparum development is attenuated in HbAS and HbSS red cells under low oxygen tension [37, 38] , and that these cells manifest altered miRNA profiles [39] . Remarkably, the investigators demonstrated that host miRNAs are transported into the parasite, wherein they can fuse with parasite mRNA to produce chimeric host-parasite RNAs, which demonstrate aberrant translation and function. Furthermore, transfection of infected HbAA red cells with host miRNAs that are overexpressed in HbAS and HbSS red cells impaired parasite development, modulated parasite metabolic pathways, and increased parasite differentiation into gametocytes. Given recent developments in the therapeutic targeting of human miRNAs as a treatment for other infections [40] , these novel miRNA activities in the host-parasite relationship may represent another pathway for attenuating the virulence of P. falciparum. A recent study using murine models of HbS and experimental cerebral malaria explored the interactions between HbS, Plasmodium spp., and the innate immune system. Ferreira et al. [33] infected mice with the Plasmodium berghei 'ANKA' strain and demonstrated that, similar to humans with HbAS, mice with a sickle-cell trait phenotype did not develop cerebral malaria. These mice expressed higher levels of heme oxygenase-1 (HO-1), and deletion of the hmox1 gene abrogated the protection afforded by the murine sickle-cell trait. Furthermore, induction of HO-1 attenuated the elaboration of chemokines implicated in the pathogenesis of cerebral malaria. Heme itself was protective against murine cerebral malaria when present in small amounts prior to infection, but deleterious when administered in large amounts after infection. Together, this series of experiments suggests that HbAS, by keeping free heme levels chronically elevated, constitutively induces the production of HO-1, which mitigates heme toxicity after Plasmodium infection, and suppresses chemokine levels that normally cause cerebral malaria. By exploring similar or unrelated mechanisms that enable HbAS children to 'tolerate' Plasmodium infection (Fig. 2) [42], we may discover strategies to prevent the development of severe and fatal malaria syndromes.
Effects on antiparasitic immunity

CONCLUSION
Recent studies have successfully identified red cell variants that confer protection from falciparum and vivax malaria, and have used some of these variants as models to explore the pathogenesis of falciparum malaria. These latter studies have uncovered novel mechanisms of disease protection in which: parasite mRNA and host miRNA fuse to constitute chimeric mRNA with altered translation; P. falciparum parasites mine host red cell actin in order to remodel the cytoskeleton and enable trafficking of parasite proteins to the red cell surface; and chronic activation of HO-1 and alteration of chemokine profiles mitigates murine cerebral malaria. These findings reflect promising opportunities to develop future preventive and therapeutic interventions for malaria.
Timmann C, Thye T, Vens M, et al. Genome-wide association study indicates two novel resistance loci for severe malaria. Nature 2012; 489:443-446. In this GWAS of severe falciparum malaria in Ghanaian children, three of four loci achieving genome-wide significance encoded red cell traits: b-globin, ABO type, and the principal Ca 2þ pump in the red cell. This completely novel latter finding was replicated in a Gambian cohort and awaits functional characterization as a new red cell trait mediating protection from severe malaria. In this longitudinal study of Ugandan children in an area highly endemic for falciparum malaria, age modified the nature and degree of protection afforded by HbAS, suggesting that sickle-cell trait exerts its malaria protective effects partly through acquired mechanisms. 25. Field studies have suggested that iron deficiency anemia protects children from falciparum malaria, and this study reported convincing proof of this from a methodologically rigorous longitudinal study and analysis in Tanzanian children. The cellular and molecular mechanisms of protection conferred by this acquired trait remain largely undescribed.
